India's 1st Covid antidote: Scientists finish Ph-2 trials

Researchers from the University of Hyderabad (UoH) and the Centre for Cellular and Molecular Biology (CCMB) have successfully completed phase 2 clinical trials of India's first antidote for Covid-19 that works across all variants circulating in the current pandemic. The scientists say the antidote also has the capacity to target variants that may emerge in the future. Called Vincov-19, the drug is said to be more effective than monoclonal antibodies that target specific variants.

from Hyderabad News: Latest Hyderabad News Headlines & Live News Updates from Hyderabad - Times of India https://ift.tt/WMGRk0N